{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"50.9","upperLimit":"91.3","value":"75"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"Will be graded according to Common Terminology Criteria for Adverse Events version 5.0. Any eligible patient who receives at least one dose of protocol therapy will be considered in the evaluation of toxicity. A patient will be counted only once for a given toxicity for the worst grade of that toxicity reported for that patient.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive tazemetostat PO BID on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Tazemetostat)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"From initiation of treatment to disease progression, disease recurrence, or death from any cause assessed up to 2 years","title":"Percentage of Patients Experiencing Grade 3 or 4 Adverse Events","type":"SECONDARY","unitOfMeasure":"percentage of participants"}